Loading...
Please wait, while we are loading the content...
Similar Documents
Profile of inotuzumab ozogamicin and its potential in the treatment of acute lymphoblastic leukemia
| Content Provider | Paperity |
|---|---|
| Author | Thomas, Xavier |
| Abstract | Profile of inotuzumab ozogamicin and its potential in the treatment of acute lymphoblastic leukemia Xavier Thomas Hospices Civils de Lyon, Hematology, Lyon-Sud Hospital, Pavillon Marcel Bérard, France Abstract: Monoclonal antibodies are likely to make a considerable contribution in the treatment of acute lymphoblastic leukemia (ALL). High expression of CD22 antigen is found on the surface of leukemia cells in ALL. Inotuzumab ozogamicin, a CD22 monoclonal antibody conjugated to calicheamicin, which has shown efficacy in patients with lymphomas, has also shown encouraging activity in relapsed or refractory ALL with a high morphologic and molecular response rate. This article summarizes the current approaches to treating ALL with inotuzumab ozogamicin, based on available data from the literature. Keywords: monoclonal antibody, inotuzumab ozogamicin, CMC-544, acute lymphoblastic leukemia, targeted therapy |
| Starting Page | 1 |
| Ending Page | 8 |
| File Format | HTM / HTML |
| ISSN | 11799889 |
| DOI | 10.2147/BLCTT.S49048 |
| Journal | Blood and Lymphatic Cancer : Targets and Therapy |
| e-ISSN | 11799889 |
| Language | English |
| Publisher | Dove Medical Press |
| Publisher Date | 2014-04-17 |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |